Selzentry - 2007 FDA approvals

Drug: Selzentry (maraviroc)
Indication: HIV
Company: Pfizer
Approval Date: August 6, 2007

Scoop: Selzentry is a CCR5 antagonist, which prevents the virus from entering white blood cells. The process reduces viral load and boosts T-cell count. For Pfizer, it was a much-needed win on the regulatory side after a series of disappointing setbacks in its pipeline development program.

More news:
Selzentry approval marks big win for Pfizer. Report
Investors yawn at Maraviroc endorsement. Report
New HIV drugs offer breakthrough therapies. Report

Selzentry - 2007 FDA approvals
Read more on

Suggested Articles

Researchers are studying the retrovirus KoRV-A, which is spreading among koalas, to gain new insights into how DNA evolves.

Shionogi and Hsiri Therapeutics first joined forces last year in a licensing and R&D deal focused on tuberculosis and non-tuberculous lung infections.

The efficacy results suggest the experimental oral therapy, abrocitinib, has a shot at challenging the blockbuster biologic incumbent.